Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2006

View Archived Issues

PRECiSE trials detail safety and efficacy of certolizumab in Crohn's disease

Methylnaltrexone shows efficacy in patients with opioid-induced constipation

VX-950 plus peg-interferon and ribavirin leads to undetectable hepatitis C virus

Studies show improved airway function with arformoterol in COPD patients

Dabigatran safety assessed in long-term open-label follow-up study

Clinical data on TNFerade in esophageal and pancreatic cancer reported

INKP-102 demonstrates superiority to Visicol in colonoscopy patients

Astellas files for Japanese approval of once-daily tacrolimus

New study of single dose velafermin for prevention of oral mucositis

Reduction in viral load in 10-day HIV study of SP-01A

Tissue Therapies' VitroGro used for culture of human embryonic stem cells

U.K. clearance for phase IIa study of BrachySil for pancreatic cancer

Dainippon licenses Dops rights to Chelsea Therapeutics

SC-409: p38 inhibition with therapeutic potential for asthma, COPD and RA

Evidence that systemic application of XG-102 is neuroprotective postischemic stroke

Merck corrects statistical method description used in Vioxx APPROVe study

Crucell tests H9N2 virosomal vaccine for avian flu

ImmuFact IMP-321 completes phase I studies

Avantogen and Innovate Oncology complete merger of key oncology program

VaxGen ends early stage meningitis B vaccine collaboration

Lyrica licensed in U.K. for GAD

Rotarix launched in U.K.

Macugen, new wet AMD treatment in U.K.

Novel antiinfective agents disclosed in recent patent literature

Novel agents for cardiovascular disorders disclosed in recent patent literature

Sphingosine kinase activators for dermatological disorders claimed in NeoPharm patent

New class of antimicrobial hexapeptides developed at Helix BioMedix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...